EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches

Ray Manneh iD, Carmen Alaez Verson iD, Angel Martin iD, Arturo Delgado, Pedro H Isaacsson Velho iD, Alejandro Manduley, Luis Tejado iD, Yolanda Rodríguez, Carmen Vargas iD, Pedro C Barata iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00628 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Ray Manneh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Hauptthemen laut MEDLINE: Mutation, Prostatic Neoplasms, Castration-Resistant, Recombinational DNA Repair. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The prevalence of homologous recombination repair gene mutations (HRRm) in patients with metastatic castration-resistant prostate cancer (mCRPC) in Latin America and the Caribbean (LAC) is unknown. Prevalence of homologous Recombination repair (HRR) gene mutatiOns in patientS with metastatic castration resistant ProstatE Cancer in LaTin America (PROSPECT) aimed to determine this prevalence and to describe the demographic and clinical characteristics of the participants. MATERIALS AND METHODS This was a prospective, cross-sectional, multicenter study across 11 cancer centers in seven LAC countries. After informed consent, all eligible participants underwent genomic testing by provided blood samples for germline HRR testing; they also provided PC tissue blocks if available for somatic HRR testing. RESULTS Between April 2021 and April 2022, 387 patients (median age, 70 years [49-89], 94.3% Eastern Cooperative Oncology Group 0-1) with mCRPC were enrolled in the study. Almost 40% of them had a family history of cancer, and the overall time from their initial PC and mCRPC diagnosis was 3 years and 1 year, respectively. The overall prevalence of germline HRRm was 4.2%. The mutations detected included the genes CHEK2 (n = 4, 1%), ATM (n = 3, 0.8%), BRCA2 (n = 3, 0.8%), BRIP1 (n = 2, 0.5%), RAD51B (n = 2, 0.5%), BRCA1 (n = 1, 0.3%), and MRE11 (n = 1, 0.3%). The prevalence of somatic HRRm could not be assessed because of high HRR testing failure rates (79%, 199/251) associated with insufficient DNA, absence of tumor cells, and poor-quality DNA. CONCLUSION Despite the study's limitations, to our knowledge, PROSPECT was the first attempt to describe the prevalence of HRRm in patients with PC from LAC. Notably, the germline HRRm prevalence in this study was inferior to that observed in North American and European populations. The somatic HRR testing barriers identified are being addressed by several projects to improve access to HRR testing and biomarker-based therapies in LAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationProstatic Neoplasms, Castration-ResistantRecombinational DNA RepairHumansMaleAgedProspective StudiesMiddle AgedCross-Sectional StudiesLatin AmericaAged, 80 and overPrevalence

Autor:innen und Institutionen

  • Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
  • Laboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica, Ciudad de Mexico, Mexico.
  • Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Centro Médico Nacional Siglo XXI, Ciudad de Mexico, Mexico.
  • Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Centro de Especialidades Urológicas de Panama, Panama City, Panama.

ORCID-Profile: Ray Manneh, Carmen Alaez Verson, Angel Martin, Pedro H Isaacsson Velho, Luis Tejado, Carmen Vargas, Pedro C Barata

Zitieren

APA

Manneh, R., Verson, C. A., Martin, A., Delgado, A., Isaacsson Velho, P. H., Manduley, A., Tejado, L., Rodríguez, Y., Vargas, C., & Barata, P. C. (2024). Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches. JCO Precision Oncology. https://doi.org/10.1200/po.23.00628

Vancouver

Manneh R, Verson CA, Martin A, Delgado A, Isaacsson Velho PH, Manduley A, et al. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches. JCO Precision Oncology. 2024. doi:10.1200/po.23.00628

BibTeX
@article{Manneh2024,
  author = {Manneh, Ray and Verson, Carmen Alaez and Martin, Angel and Delgado, Arturo and Isaacsson Velho, Pedro H and Manduley, Alejandro and Tejado, Luis and Rodríguez, Yolanda and Vargas, Carmen and Barata, Pedro C},
  title = {Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00628}
}
Kostenlos starten →